Matson maintained a neutral stance on Zimmer Biomet Holdings stock, noting the influence of ZBH's acquisition strategy on analyst outlook.
1 report, 1 independent
Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Matson maintained a neutral stance on Zimmer Biomet Holdings stock, noting the influence of ZBH's acquisition strategy on analyst outlook.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Zimmer Biomet Holdings is leveraging clinical expertise to influence its product pipeline and challenge the core orthopedics and robotics market.Also in this story
- Gary Campbell was promoted to President, Americas, and Kessler was promoted to President, Americas – Robotics.
- Stryker's strong sales are threatening Zimmer Biomet's market share in the medical device sector.
The entities involved
-
Zimmer Biomet Holdings
medical device company
Nothing else this week.
-
Michael Matson
American ocean rower and chemist
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyNeedham Maintains a Neutral Stance on Zimmer Biomet Holdings (ZBH) Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is one of the best undervalued medical device stocks to buy now. On July 10, Needham analyst